---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-028332"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:56:59.282897+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Apimeds Pharmaceuticals to effect 1-for-10 reverse stock split on March 26, 2026

## Summary
- Stockholders approved 1-for-10 reverse stock split via written consent in December 2025.
- Reverse split effective 12:01 a.m. ET March 26, 2026; trading begins on split-adjusted basis same day.
- Every 10 pre-split shares convert to 1 share; new CUSIP 03771D201.
- Company expects to file charter amendment with Delaware Secretary of State around March 25.

## SEC filing metadata
- accession: 0001213900-26-028332
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390026028332/0001213900-26-028332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390026028332/ea0281820-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-028332
- JSON: https://secwatch.observer/filing/0001213900-26-028332.json
- Plain text: https://secwatch.observer/filing/0001213900-26-028332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.